CAS
ABCL icon

CTC Alternative Strategies’s AbCellera Biologics ABCL Stock Holding History

CTC Alternative Strategies’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-18,100
Closed -$117K – 75
2023
Q2 		$117K Buy
+18,100
New +$124K 0.15% 129

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

CTC Alternative Strategies's ABCL Position: Q3 2023 in Review

CTC Alternative Strategies sold out of AbCellera Biologics (ABCL) in Q3 2023, closing a stake of 18,100 shares — an estimated $117K sold.

CTC Alternative Strategies first reported a position in ABCL in Q2 2023 and held it in 1 quarter. The position peaked at $117K in Q2 2023. 138 funds tracked by Wall St. Rank hold ABCL as of Q3 2023.

  • CTC Alternative Strategies reported no remaining AbCellera Biologics position as of Q3 2023 after selling out during the quarter.
  • CTC Alternative Strategies sold 18,100 AbCellera Biologics shares in Q3 2023, an estimated $117K.
  • CTC Alternative Strategies first reported a position in AbCellera Biologics in Q2 2023 and held it in 1 quarter.
  • CTC Alternative Strategies's AbCellera Biologics position peaked at $117K in Q2 2023.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2023.

Based on CTC Alternative Strategies's 13F filing for Q3 2023, filed 31 Oct 2023.